Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Guggenheim

Guggenheim assumed coverage on shares of Immunome (NASDAQ:IMNM) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $35.00 target price on the stock.

A number of other analysts also recently commented on the company. SVB Leerink started coverage on Immunome in a report on Monday, January 29th. They set an outperform rating and a $30.00 price objective for the company. Leerink Partnrs reiterated an outperform rating on shares of Immunome in a report on Monday, January 29th. Finally, Wedbush increased their price target on Immunome from $27.00 to $33.00 and gave the company an outperform rating in a report on Monday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome currently has a consensus rating of Buy and an average target price of $32.67.

Immunome Stock Performance

Shares of IMNM opened at $17.18 on Monday. The stock has a fifty day moving average of $23.03 and a two-hundred day moving average of $14.81. The company has a market capitalization of $1.03 billion, a PE ratio of -3.19 and a beta of 1.66. Immunome has a fifty-two week low of $4.44 and a fifty-two week high of $30.96.

Institutional Investors Weigh In On Immunome

Several large investors have recently made changes to their positions in IMNM. Dorsey Wright & Associates acquired a new position in shares of Immunome during the third quarter valued at approximately $26,000. Natixis acquired a new position in shares of Immunome during the fourth quarter valued at approximately $25,000. Renaissance Technologies LLC acquired a new position in shares of Immunome during the first quarter valued at approximately $80,000. First Republic Investment Management Inc. acquired a new position in shares of Immunome during the first quarter valued at approximately $87,000. Finally, UBS Group AG increased its stake in shares of Immunome by 1,049.9% during the third quarter. UBS Group AG now owns 15,271 shares of the company’s stock valued at $68,000 after acquiring an additional 13,943 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.